STRUCTURAL HEART
TAVR with 29mm Evolut-R CoreValve – September 2017

79 year old female presented with progressive dyspnea (NYHA Class III) and a decrease in exercise tolerance <1 block. Past medical history is significant for severe aortic stenosis, CAD (s/p PCI in 2008), diabetes mellitus, hypertension, hypercholesterolemia, pulmonary hypertension, hepatitis C, non-hodgkins lymphoma, hypothyroidism, DJD spine and GERD . Recent echocardiogram revealed progression to severe aortic stenosis (PG/MG/AVA 74mmHg/50mmHg/0.57cm2) and LVEF of 58%. CT angiogram revealed bilateral lower extremity and left upper extremity arterial access had minimal diameter < 6mm but the right upper extremity artery access >6mm. The aortic annulus measured 21x26mm (average 23.6mm) and the annular perimeter was 76mm. STS mortality risk for surgical AVR was 3.6% and the logistic Euroscore mortality risk was 8.9%. Patient underwent surgical evaluation and was found to be at high risk for SAVR. Now presents for TAVR with 29mm Evolut-R CoreValve via the right subclavian artery cutdown.

48:25

comments

Leave Your Comments

Your email address will not be published. Required fields are marked *

*

suggestion
Suggestions
Valve-in-Valve TAVR with 29mm Evolut-R CoreValve – January 2019
Views266

79 year old man presents with progressive exertional dyspnea (NYHA Class III) for the last 2 months.


TAVR 29mm Sapien-3 – November 2018
Tags:
Views504

96 year old male presents with progressive exertional dyspnea (NYHA Class III) for the last 4 months.


TAVR in a Patient with Prior Mitral Valve Replacement – September 2018
Tags: |
Views537

87 year old female presents with progressive exertional dyspnea (NYHA Class III) for the last 3 months.


Edge-to-Edge Mitral Valve Repair with MitraClip – July 2018
Tags: | |
Views654

87 year old male with known history of mitral regurgitation, hypertension, hyperlipidemia, CAD s/p DES PCI to RCA (2010 and 2015), ischemic cardiomyopathy, carotid artery stenosis, and frailty presents with worsening dyspnea on exertion NYHA Class III for 6 months.